SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals reports stellar Q1 numbers

08 May 2012 Evaluate

GlaxoSmithKline Pharmaceuticals has reported a jump of over 267 times in its net profit at Rs 122.89 crore for the first quarter ended March 31, 2012 as compared to Rs 0.46 crore for the same quarter last year.

The company’s total income has increased to Rs 703.19 crore, up by 6.40% from Rs 660.91 crore in the corresponding quarter previous year.

GlaxoSmithKline Pharmaceuticals is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.

Glaxosmithkline Phar Share Price

2440.30 21.20 (0.88%)
17-Apr-2026 11:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1680.10
Dr. Reddys Lab 1222.90
Cipla 1239.65
Zydus Lifesciences 945.05
Lupin 2320.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×